The prognostic and predictive value of the 8th American Joint Committee on Cancer (AJCC) staging system among early breast cancer patients aged <50 years

Purpose: To evaluate how implementation of the 2003 American Joint Committee on Cancer (AJCC) staging system will affect stage-specific survival of breast cancer patients. Patients and Methods: Records of 1,350 patients treated on sequential institutional protocols with mastectomy and adjuvant doxorubicin-based chemotherapy were reviewed. Pathologic stage was assigned retrospectively according to the 1988 and the 2003 AJCC staging criteria. Overall stage-specific survival (OS) was calculated using the Kaplan-Meier method, and hypothetical differences were compared by the log-rank test. Results: Six hundred five of 1,087 patients with stage II disease according to the 1988 classification system had stage II disease according to the 2003 system. The 10-year OS for patients with stage II disease was significantly improved using the 2003 system (76% [2003] v 65% [1988]; P < .0001). Two hundred eighty-nine of 633 patients with stage IIb disease using the 1988 system were stage IIb with the 2003 system, and 10-year OS was 58% (1988) versus 70% (2003; P = .003). The number of patients with stage III disease increased from 207 (1988) to 443 (2003), and the 10-year OS changed from 45% (1988) to 50% (2003; P = .077). Most of this difference resulted from changes within stage IIIa: OS, 45% (1988) versus 59% (2003; P < .0001). Conclusion: Stage reclassification using the new AJCC staging system for breast cancer will result in significant changes in reported outcome by stage. It is imperative that careful attention is devoted to this effect so that accurate conclusions regarding the efficacy of new treatment strategies can be drawn.

Download Full-text

The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2- Enriched Subtype Breast Cancer, a Retrospective Analysis

Anticancer Research ◽

10.21873/anticanres.11862 ◽

2017 ◽

Vol 37 (8) ◽

Cited By ~ 1

Keyword(s):

Breast Cancer ◽

Retrospective Analysis ◽

Prognostic Value ◽

Staging System ◽

American Joint Committee ◽

Ajcc Staging System ◽

Ajcc Staging ◽

8Th Edition

Download Full-text

Predictive Value of Primary Tumor Site for Locoregional Recurrence in Early Breast Cancer Patients With 1 to 3 Positive Axillary Lymphadenophy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2016.06.657 ◽

2016 ◽

Vol 96 (2) ◽

pp. E25-E26

Author(s):

B. Wen ◽

S. Niu ◽

C. Wang ◽

Y. Zhang

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Early Breast Cancer ◽

Primary Tumor ◽

Predictive Value ◽

Locoregional Recurrence ◽

Tumor Site ◽

Breast Cancer Patients ◽

Primary Tumor Site

Download Full-text

Implications for the American Joint Committee on Cancer staging systems on esophageal squamous cell cancer patients receiving multimodality therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.3_suppl.123 ◽

2014 ◽

Vol 32 (3_suppl) ◽

pp. 123-123

Author(s):

Motoo Nomura ◽

Tetsuya Abe ◽

Azusa Komori ◽

Yukiya Narita ◽

Shiori Uegaki ◽

...

Keyword(s):

Regression Model ◽

Cancer Patients ◽

Squamous Cell ◽

Cell Cancer ◽

Staging System ◽

Prognostic Impact ◽

American Joint Committee ◽

Staging Systems ◽

Ajcc Staging System ◽

Ajcc Staging

123 Background: The 7th edition of the American Joint Committee on Cancer (AJCC) staging system is based on pathologic data from esophageal cancers treated by surgery alone. The objective of this study was to evaluate the prognostic impact of the pretreatment clinical stage (cTNM) and posttreatment pathologic stage (ypTNM) on esophageal cancer patients undergoing neoadjuvant chemotherapy followed by surgery (NAC-S). Methods: Information on 245 consecutive esophageal squamous cell carcinoma patients undergoing NAC-S was reviewed. Data collected included demographics, cTNM, ypTNM, and survival. Statistical methods included the Cox regression model, Akaike information criterion (AIC) within the Cox proportional hazard regression model, and Kaplan-Meier analyses. Results: The overall three-year survival rate was 67.6%. There were significant differences between stages II and III in cTNM and ypTNM stage, respectively (P < 0.01, respectively). There were no significant survival differences between stages I and II, between stages III and IV in each TNM stage. For all patients, cN stage (cN0 vs. cN1-3), ypT stage (ypT0-2 vs. ypT3-4), ypN stage (N0 vs. N1-3), and ypM stage were independent prognostic factors by multivariate analysis (P< 0.05). Compared with cTNM stage, ypTNM stage has a smaller AIC value, which described the optimum prognostic stratification. Conclusions: Our study indicates that the ypTNM stage of the 7th edition of AJCC staging system has better performance than the cTNM stage in patients undergoing NAC-S.

Download Full-text